New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2013
07:45 EDTPRTAProthena price target raised to $38 from $30 at RBC Capital
RBC Capital increased its price target on Prothena (PRTA) after the company announced a worldwide partnership with Roche (RHHBY) on PRX-002 for Parkinson's disease. The firm thinks the deal creates potential value on an asset that previously was given little credit, while validating Prothena's expertise. The firm keeps an Outperform rating on the shares.
News For PRTA From The Last 14 Days
Check below for free stories on PRTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
10:06 EDTPRTAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:08 EDTPRTAProthena initiated with a Buy at Citigroup
Subscribe for More Information
April 8, 2014
16:10 EDTPRTAProthena says first human dosed in Phase 1 study of PRX002
Prothena (PRTA) announced the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15M milestone payment from Roche (RHHBY) related to the initiation of this study. The initial Phase 1 clinical trial of PRX002 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects. It is designed to assess PRX002 for safety, tolerability, pharmacokinetics and immunogenicity. As previously announced in December 2013, Prothena entered into a worldwide collaboration with Roche to develop and commercialize antibodies that target α-synuclein, including PRX002. Including the current milestone payment, Prothena has now achieved a total of $45M through its worldwide PRX002 collaboration with Roche.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use